A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults

Trial Profile

A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Acumapimod (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms AETHER
  • Sponsors Mereo BioPharma
  • Most Recent Events

    • 11 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 May 2017 Top-line data from this study are expected in the second half of 2017, according to a Mereo BioPharma media release.
    • 12 Dec 2016 According to Mereo BioPharma media release, this study is on track to deliver data in H2 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top